Edition:
United States

People: Acceleron Pharma Inc (XLRN.OQ)

XLRN.OQ on NASDAQ Stock Exchange Global Market

48.04USD
12:35pm EDT
Change (% chg)

$-0.35 (-0.72%)
Prev Close
$48.39
Open
$48.57
Day's High
$48.58
Day's Low
$47.70
Volume
29,702
Avg. Vol
122,221
52-wk High
$50.00
52-wk Low
$32.48

Dable, Habib 

Mr. Habib J. Dable is President, Chief Executive Officer, Director of the Company. He has served as our Chief Executive Officer and President and a member of our Board of Directors since December 2016. Mr. Dable is a seasoned pharmaceutical executive, with experience in maximizing the potential of new therapies and successfully implementing innovative U.S. and global product launches. Since 1994, Mr. Dable has served in roles of increasing responsibility at Bayer AG, serving since October 2015 as the President of Pharmaceuticals for Bayer in the U.S. From 2013 to 2015, Mr. Dable served as the Executive Vice President and Global Head of Specialty Medicine for Bayer HealthCare Pharmaceuticals, and from 2010 to 2012, he was the Vice President of Ophthalmology & Global Launch Team Head for EYLEA. Mr. Dable earned both Bachelor’s and Master’s degrees of Business Administration from the University of New Brunswick in Canada. We believe Mr. Dable’s executive leadership experience and industry knowledge qualify him to serve as a member of our Board of Directors.

Basic Compensation

Total Annual Compensation, USD 550,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 772,314
Fiscal Year Total, USD 1,322,310

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Francois Nader

245,291

Habib Dable

1,322,310

Kevin McLaughlin

1,570,900

John Quisel

1,692,320

Ravindra Kumar

1,510,260

Sujay Kango

--
As Of  30 Dec 2017